PDIA3

Across TCGA pan-cancer cohorts, PDIA3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDIA3 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDIA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDIA3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PDIA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.774	0.418	.002	24	view →
CCRCC	OS	Median	All	0.629	1.000	.002	18	view →
LUAD	OS	Tertile	II,III,IV	0.381	0.715	.018	9	view →
GBM	DFS	Quartile	All	0.579	0.302	.020	6	view →
LSCC	OS	Tertile	II,III,IV	0.680	0.946	.034	5	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDIA3–PDAC (OS)

Open the PDAC breakdown →